Well we knew this was coming and it’s exceptionally tricky in...

Well we knew this was coming and it’s exceptionally tricky in the current climate for biotechs in particular to raise funds. the fact management are still committed and investing deep despite their own personal losses is good.

always a little disappointed in some of the commentary around management and the remarks made here. Ultimately the one thing management can control is the companies execution on acquiring technology, get approvals for trials and supporting them getting done. For this I think Jennifer’s done an outstanding job and I feel confident in her ability to help formulate trials in the most optimal way under the current FDA guidelines.

Although I do somewhat mourn for the $$ sunk and lost so far, I’m not going to allow this to bias me from making a further investment. The pipeline seems healthy and solid, and we have some readouts in the near term that I think will be interesting.

ill be in for the SPP

cheers, YS